Morgan Stanley analyst David Bailey raised the firm’s price target on ResMed (RMD) to $305 from $304 and keeps an Overweight rating on the shares after the company delivered a “slightly better-than-expected” fiscal Q1 result, supported by “solid” operating leverage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Resmed’s Strong Growth and Future Potential: Buy Rating Affirmed
- ResMed price target lowered to $300 from $310 at Mizuho
- Resmed’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Resmed Inc. Reports Strong Start to Fiscal 2026
- Resmed Announces Quarterly Dividend Amid Strong Q1 Results